Pemvidutide
Sources
registry, as of 2026-07-31Stale
https://clinicaltrials.gov/study/NCT06987513
RECLAIM STUDY: Phase 2 Study of the Efficacy and Safety of Pemvidutide in the Treatment of Alcohol Use Disorder (AUD) in Subjects With Obesity or Overweight. Overall status COMPLETED. Phases PHASE2. Lead sponsor Altimmune, Inc.. Enrollment 100. Conditions Alcohol Use Disorder (AUD). This is a Phase 2, multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of pemvidutide in the treatment of AUD in subjects with obesity or overweight. After signing the informed consent form, subjects will be screened and if eligible
ClinicalTrials.gov NCT06987513 protocol and results modules
publication, as of 2024-12-18Stale
https://pubmed.ncbi.nlm.nih.gov/39002641/
was a randomized, double-blind, placebo-controlled study to assess the effects of pemvidutide, a glucagon-like peptide-1 (GLP-1)/glucagon dual receptor agonist, on liver fat content (LFC) in individuals with metabolic dysfunction-associated steatotic liver disease (MASLD). Patients with a BMI ≥28.0 kg/m 2 and LFC ≥10%
PMID 39002641